Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 57, Issue 11, Pages 799-804Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-001-0396-3
Keywords
cytochrome P-450; inhibition; interaction; isoniazid
Categories
Ask authors/readers for more resources
Objective: In order to evaluate the inhibitory effects of isoniazid on cytochrome P-450 (CYP) mediated drug metabolism, the in vitro inhibitory potency and specificity as well as the reduced nicotinamide adenine dinucleotide phosphate (NADPH)-, time- and concentration dependency of isoniazid as an inhibitor of the activity of the major human CYP isoforms were studied. Methods: Using pooled human liver microsomes, the in vitro inhibitory effects of isoniazid on CYP1A2 (phenacetin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2C9 (tolbutamide hydroxylation), CYP2C19 (S-mcphenytoin 4'-hydroxylation), CYP2D6 (dextromethorphan O-demethylation), CYP2E1 (chlorzoxazone 6-hydroxylation) and CYP3A4 (midazolam 1'-hydroxylation) activities were examined. Results: After a 15-min preincubation without NADPH, isoniazid reversibly inhibited microsomal CYP2C19- and CYP3A4-mediated reactions with apparent K-i values of 36 muM and 73 muM, respectively. However, isoniazid had only weak inhibitory effects on the five other CYP-mediated reactions (K-i > 110 muM). After a 15-min preincubation with NADPH, isoniazid showed an increased inhibitory potency toward CYP1A2, CYP2A6, CYP2C19 and CYP3A4 activities (K-i=56, 60, 10 and 36 muM, respectively). In addition, the inactivation of CYP1A2, CYP2A6, CYP2C19 and CYP3A4 by isoniazid was NADPH-, time- and concentration dependent, and was characterised by K-inact values of 0.11, 0.13, 0.09 and 0.08 min(-1), and K-i values of 285, 173, 112 and 228 M, respectively. Conclusions: As the peak plasma concentrations of isoniazid are around 30-50 muM, isoniazid at clinically relevant concentrations reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 in human liver microsomes. Co-administration of isoniazid and drugs that are primarily metabolised by these CYP isoforms, particularly by CYP2C19 and CYP3A4, may result in significant drug interactions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available